litlas
Log inCreate account

Peter McLaughlin

Active 1976–2023

90
Papers
19,411
Citations
80
h-index
87
i10-index

Citations

Citations per year for Peter McLaughlin1977: 3 citations1978: 5 citations1979: 4 citations1980: 6 citations1981: 10 citations1982: 4 citations1983: 5 citations1984: 4 citations1985: 3 citations1986: 6 citations1987: 9 citations1988: 8 citations1989: 16 citations1990: 11 citations1991: 26 citations1992: 16 citations1993: 36 citations1994: 38 citations1995: 41 citations1996: 25 citations1997: 30 citations1998: 42 citations1999: 53 citations2000: 94 citations2001: 105 citations2002: 114 citations2003: 161 citations2004: 150 citations2005: 187 citations2006: 171 citations2007: 182 citations2008: 188 citations2009: 190 citations2010: 188 citations2011: 146 citations2012: 126 citations2013: 114 citations2014: 126 citations2015: 100 citations2016: 69 citations2017: 92 citations2018: 68 citations2019: 215 citations2020: 212 citations2021: 179 citations2022: 100 citations2023: 70 citations2024: 80 citations2025: 42 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,520 citing papers, 32.5% of this breakdownUnited Kingdom: 339 citing papers, 7.2% of this breakdownGermany: 312 citing papers, 6.7% of this breakdownFrance: 301 citing papers, 6.4% of this breakdownItaly: 296 citing papers, 6.3% of this breakdownCanada: 192 citing papers, 4.1% of this breakdownSpain: 151 citing papers, 3.2% of this breakdownAustralia: 147 citing papers, 3.1% of this breakdownChina: 136 citing papers, 2.9% of this breakdownSwitzerland: 126 citing papers, 2.7% of this breakdownNetherlands: 124 citing papers, 2.7% of this breakdownJapan: 106 citing papers, 2.3% of this breakdown
0%32.5%Other 19.9%

Institutions

Fields

  • Medicine81.6%
  • Biochemistry, Genetics and Molecular Biology7%
  • Immunology and Microbiology5.7%
  • Neuroscience1.2%
  • Materials Science1%
  • Agricultural and Biological Sciences0.8%
  • Other2.7%

Topics

  • Lymphoma Diagnosis and Treatment16.9%
  • Chronic Lymphocytic Leukemia Research7.9%
  • Viral-associated cancers and disorders4.7%
  • CAR-T cell therapy research3.9%
  • CNS Lymphoma Diagnosis and Treatment3.9%
  • Monoclonal and Polyclonal Antibodies Research3.4%
  • Other59.3%

Coauthors

All papers

Open in search
  1. Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

    Authors: Massimo Federico, Monica Bellei, Luigi Marcheselli, Stefano Luminari, Armando López‐Guillermo, Umberto Vitolo, Barbara Pro, Stefano Pileri, Alessandro Pulsoni, Pierre Soubeyran, Sergio Cortelazzo, Giovanni Martinelli, Maurizio Martelli, Luigi Rigacci, Luca Arcaini, Francesco Di Raimondo, Francesco Merli, Elena Sabattini, Peter McLaughlin, Philippe Solal‐Céligny - Journal of Clinical Oncology 2009 cited by 751

  2. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    Authors: Peter McLaughlin, A.J. Grillo-López, Brian K. Link, Ronald Levy, M. S. Czuczman, Michael E. Williams, Meyer R. Heyman, Isabelle Bence‐Bruckler, Christine A. White, Fernando Cabanillas, Vinay Jain, Anthony D. Ho, John Lister, Ken Wey, Diying Shen, B.K. Dallaire - Journal of Clinical Oncology 1998 cited by 2,759

  3. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Authors: Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak, Liang Zhang, Fredrick Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Peter McLaughlin, Michelle A. Fanale, Anas Younes, Fernando Cabanillas, Nathan Fowler, Kate J. Newberry, Luhong Sun, Ken H. Young, Richard E. Champlin, Larry W. Kwak, Lei Feng, Maria Badillo, Maria Teresa Bejarano, Kimberly Hartig, Wendy Chen, Yi‐Ming Chen, Catriona Byrne, Neda Bell, Jerome B. Zeldis, Jorge Romaguera - The Lancet Oncology 2012 cited by 297

  4. Nontypeable Haemophilus influenzae Induces Sustained Lung Oxidative Stress and Protease Expression

    Authors: Paul T. King, Roleen Sharma, Kim M. O’Sullivan, Stavros Selemidis, Steven Lim, Naghmeh Radhakrishna, Camden Lo, Jyotika D. Prasad, Judy M. Callaghan, Peter McLaughlin, Michael Farmer, Daniel Steinfort, Barton R. Jennings, James Ngui, Bradley Broughton, Belinda J. Thomas, Ama‐Tawiah Essilfie, Michael J. Hickey, Peter W. Holmes, Philip M. Hansbro, Philip G. Bardin, Stephen R. Holdsworth - PLoS ONE 2015 cited by 80

  5. The Novel Cannabinoid CB1 Receptor Neutral Antagonist AM4113 Suppresses Food Intake and Food-Reinforced Behavior but Does not Induce Signs of Nausea in Rats

    Authors: Kelly S. Sink, Peter McLaughlin, Jodi Wood, C. Brown, Pusheng Fan, Kiran Vemuri, Yan Pang, Teresa Olzewska, Ganesh A. Thakur, A. Makriyannis, Linda A. Parker, John D. Salamone - Neuropsychopharmacology 2007 cited by 160

  6. Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

    Authors: Philippe Solal‐Céligny, Monica Bellei, Luigi Marcheselli, Emanuela Anna Pesce, Stefano Pileri, Peter McLaughlin, Stefano Luminari, Barbara Pro, Silvia Montoto, Andrés J.M. Ferreri, Éric Deconinck, Nöel Milpied, Leo I. Gordon, Massimo Federico - Journal of Clinical Oncology 2012 cited by 129

  7. Neuroscience explanations really do satisfy: A systematic review and meta-analysis of the seductive allure of neuroscience

    Authors: Elizabeth Bennett, Peter McLaughlin - Public Understanding of Science 2023 cited by 18

  8. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Authors: Apostolia M. Tsimberidou, Sijin Wen, Peter McLaughlin, Susan O’Brien, William G. Wierda, Susan Lerner, Sara S. Strom, Emil J. Freireich, L. Jeffrey Medeiros, Hagop M. Kantarjian, Michael J. Keating - Journal of Clinical Oncology 2008 cited by 241

  9. Long-term results with radiotherapy for stage I–II follicular lymphomas

    Authors: Richard B. Wilder, Dan Jones, Susan L. Tucker, Lillian M. Fuller, Chul S Ha, Peter McLaughlin, Mark A. Hess, Fernando Cabanillas, James D. Cox - International Journal of Radiation Oncology*Biology*Physics 2001 cited by 179

  10. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival

    Authors: A H Sarris, K. O. Kliche, P. Pethambaram, A. Preti, S. Tucker, Clotilde M. Jackow, Osvaldo Daniel Messina, William Pugh, Fredrick B. Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Jorge Romaguera, Herbert A. Fritsche, Thomas E. Witzig, Madeleine Duvic, M Andreeff, Fernando Cabanillas - Annals of Oncology 1999 cited by 163

  11. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

    Authors: Anas Younes, Jorge Romaguera, Michelle A. Fanale, Peter McLaughlin, Frederick Hagemeister, Amanda Copeland, Sattva S. Neelapu, Larry W. Kwak, Jatin J. Shah, Silvana de Castro Faria, Stefan Hart, Jeanette M. Wood, Ramesh Jayaraman, Kantharaj Ethirajulu, Joy Zhu - Journal of Clinical Oncology 2012 cited by 139

  12. Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

    Authors: Neil L. Berinstein, A.J. Grillo-López, Christine A. White, Isabelle Bence‐Bruckler, David G. Maloney, M. S. Czuczman, D. Green, J. Rosenberg, Peter McLaughlin, Diying Shen - Annals of Oncology 1998 cited by 523

  13. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

    Authors: William S. Velasquez, Peter McLaughlin, S Tucker, Fredrick B. Hagemeister, F Swan, Maria Alma Rodriguez, Jorge Romaguera, Edward Rubenstein, Fernando Cabanillas - Journal of Clinical Oncology 1994 cited by 430

  14. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

    Authors: Nathan Fowler, R. Eric Davis, Seema Rawal, Loretta J. Nastoupil, Fredrick B. Hagemeister, Peter McLaughlin, Larry W. Kwak, Jorge Romaguera, Michelle A. Fanale, Luis Fayad, Jason R. Westin, Jatin J. Shah, Robert Z. Orlowski, Michael Wang, Francesco Turturro, Yasuhiro Oki, Linda Claret, Lei Feng, Veerabhadran Baladandayuthapani, Tariq Muzzafar, Kenneth Y. Tsai, Felipe Samaniego, Sattva S. Neelapu - The Lancet Oncology 2014 cited by 263

  15. Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

    Authors: Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas Younes, Scott E. Smith, Patrick J. Stiff, Eric P. Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes, Barbara Pro - Journal of Clinical Oncology 2010 cited by 208

  16. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas.

    Authors: Rodger M. Pryzant, Marvin L. Meistrich, Gene Wilson, B Brown, Peter McLaughlin - Journal of Clinical Oncology 1993 cited by 169

  17. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions

    Authors: John D. Salamone, Peter McLaughlin, Kelly S. Sink, Alexandros Makriyannis, Linda A. Parker - Physiology & Behavior 2007 cited by 133

  18. Phase II multicenter study of oblimersen sodium, a Bcl‐2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B‐cell non‐Hodgkin lymphoma

    Authors: Barbara Pro, Brian Leber, Mitchell R. Smith, Luis Fayad, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James A. Zwiebel, Adriana López, Larry W. Kwak, Anas Younes - British Journal of Haematology 2008 cited by 105

  19. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte–predominant Hodgkin lymphoma

    Authors: Michelle A. Fanale, Chan Y. Cheah, Amy Rich, L. Jeffrey Medeiros, Chao-Ming Lai, Yasuhiro Oki, Jorge Romaguera, Luis Fayad, Fredrick B. Hagemeister, Felipe Samaniego, Maria Alma Rodriguez, Sattva S. Neelapu, Hun Ju Lee, Loretta J. Nastoupil, Nathan Fowler, Francesco Turturro, Jason R. Westin, Michael Wang, Peter McLaughlin, Chelsea C. Pinnix, Sarah A. Milgrom, Bouthaina S. Dabaja, Sandra B. Horowitz, Anas Younes - Blood 2017 cited by 88

  20. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma

    Authors: Bita Esmaeli, Peter McLaughlin, Barbara Pro, Felipe Samaniego, Isis Gayed, Fredrick B. Hagemeister, Jorge Romaguera, Fernando Cabanillas, Sattva S. Neelapu, R. Banay, Luis Fayad, M. Wayne Saville, Larry W. Kwak - Annals of Oncology 2009 cited by 88

  21. Follicular lymphoma international prognostic index.

    Authors: Philippe Solal-Céligny, Pascal Roy, Philippe Colombat, Josephine M White, Jim O Armitage, Reyes Arranz-Sáez, Wing Y Au, Monica Bellei, Pauline Brice, Dolores Caballero, Bertrand Coiffier, E. Conde-Garcia, Chantal Doyen, Massimo Federico, Richard I Fisher, Javier F Garcia-Conde, Cesare Guglielmi, Anton Hagenbeek, Corinne Haïoun, Michael LeBlanc, Andrew Lister, Armando López‐Guillermo, Peter McLaughlin, Nöel Milpied, Pierre Morel, Nicolas Mounier, Stephen J Proctor, Ama Rohatiner, Paul Smith, Pierre Soubeyran, Hervé Tilly, Umberto Vitolo, Pier Luigi Zinzani, Emanuele Zucca, Emili Montserrat - Blood 2004 cited by 1,532

  22. Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Authors: Thomas A. Davis, Antonio J Grillo-López, Christine A. White, Peter McLaughlin, Myron S. Czuczman, Brian K. Link, David G. Maloney, Robin Weaver, J. Rosenberg, Ronald Levy - Journal of Clinical Oncology 2000 cited by 689

  23. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)

    Authors: WS Velasquez, Fernando Cabanillas, P. Salvador, Peter McLaughlin, Michael Fridrik, S Tucker, Sundar Jagannath, FB Hagemeister, JR Redman, F Swan - Blood 1988 cited by 581

  24. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Authors: André Goy, Anas Younes, Peter McLaughlin, Barbara Pro, Jorge Romaguera, Frederick Hagemeister, Luis Fayad, Nam H. Dang, Felipe Samaniego, Michael Wang, Kristine Broglio, Barry I. Samuels, Frédéric Gilles, Andreas H. Sarris, Susan Hart, Elizabeth Trehu, David P. Schenkein, Fernando Cabanillas, Alma María Rodríguez - Journal of Clinical Oncology 2004 cited by 527